scholarly journals Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States

2021 ◽  
Author(s):  
Sarah S. Mougalian ◽  
Jonathan K. Kish ◽  
Jingchuan Zhang ◽  
Djibril Liassou ◽  
Bruce A. Feinberg
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Metastatic Breast Cancer ◽  
Clinical Experience ◽  
Real World ◽  
Metastatic Breast ◽  
The United States

scholarly journals Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States

2021 ◽  
Author(s):  
Sarah S. Mougalian ◽  
Jonathan K. Kish ◽  
Jingchuan Zhang ◽  
Djibril Liassou ◽  
Bruce A. Feinberg
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Metastatic Breast Cancer ◽  
Clinical Experience ◽  
Real World ◽  
Metastatic Breast ◽  
The United States

scholarly journals The Status of Chemotherapy in Metastatic Breast Cancer: Insights for the Advanced Practitioner

2021 ◽  
Vol 12 (2) ◽  
Author(s):  
Kirollos Hanna, PharmD, BCPS, BCOP ◽  
Kelley Mayden, MSN, FNP, AOCNP
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Metastatic Breast Cancer ◽  
Death Rate ◽  
Metastatic Breast ◽  
The United States ◽  
Cancer Society ◽  
Common Cause ◽  
Advanced Practitioner ◽  
The Status

Breast cancer is the most frequently diagnosed cancer in the United States and ranks second as the most common cause of cancer-related death among women (Siegel et al., 2020). According to American Cancer Society (ACS) estimates, approximately 276,480 new cases of breast cancer would have been diagnosed in 2020, and greater than 42,000 deaths would be attributed to breast cancer (ACS, 2020). Although only 7% of all cancer-related deaths are from breast cancer every year, it is the leading cause of death among women between the ages of 40 and 49 years (Siegel et al., 2020). The death rate associated with breast cancer, however, has decreased by 1.3% annually from 2013 to 2017.

Sign in / Sign up

Export Citation Format

Share Document